Vanguard Group Inc. Reduces Stake in Dynavax Technologies Corporation $DVAX

Vanguard Group Inc. lessened its stake in shares of Dynavax Technologies Corporation (NASDAQ:DVAX) by 3.9% in the third quarter, Holdings Channel reports. The institutional investor owned 8,099,758 shares of the biopharmaceutical company’s stock after selling 327,196 shares during the quarter. Vanguard Group Inc. owned about 0.07% of Dynavax Technologies worth $80,431,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Marshall Wace LLP grew its position in Dynavax Technologies by 107.2% during the second quarter. Marshall Wace LLP now owns 1,814,934 shares of the biopharmaceutical company’s stock valued at $18,004,000 after acquiring an additional 939,076 shares during the last quarter. Man Group plc grew its stake in shares of Dynavax Technologies by 925.5% during the second quarter. Man Group plc now owns 447,847 shares of the biopharmaceutical company’s stock valued at $4,443,000 after buying an additional 404,175 shares during the last quarter. Pacer Advisors Inc. raised its stake in shares of Dynavax Technologies by 3,639.9% during the third quarter. Pacer Advisors Inc. now owns 322,119 shares of the biopharmaceutical company’s stock valued at $3,199,000 after acquiring an additional 313,506 shares during the last quarter. Squarepoint Ops LLC grew its stake in shares of Dynavax Technologies by 222.3% in the second quarter. Squarepoint Ops LLC now owns 435,577 shares of the biopharmaceutical company’s stock worth $4,321,000 after purchasing an additional 300,421 shares during the last quarter. Finally, Qube Research & Technologies Ltd purchased a new position in Dynavax Technologies during the 2nd quarter valued at about $2,844,000. 96.96% of the stock is owned by hedge funds and other institutional investors.

Dynavax Technologies Stock Performance

Shares of DVAX stock opened at $15.50 on Friday. The company has a current ratio of 7.62, a quick ratio of 6.94 and a debt-to-equity ratio of 0.41. Dynavax Technologies Corporation has a 12-month low of $9.20 and a 12-month high of $15.73. The stock has a market capitalization of $1.82 billion, a P/E ratio of -41.89 and a beta of 0.97. The firm’s 50 day moving average is $15.50 and its 200 day moving average is $12.26.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Weiss Ratings restated a “sell (d)” rating on shares of Dynavax Technologies in a report on Wednesday, January 21st. William Blair cut shares of Dynavax Technologies from an “outperform” rating to a “hold” rating in a research report on Wednesday, December 24th. Finally, Wall Street Zen raised shares of Dynavax Technologies to a “strong-buy” rating in a research report on Saturday, February 14th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Dynavax Technologies currently has an average rating of “Reduce” and an average target price of $21.00.

Insider Activity

In related news, COO David F. Novack sold 114,000 shares of Dynavax Technologies stock in a transaction on Thursday, January 15th. The stock was sold at an average price of $15.64, for a total value of $1,782,960.00. Following the completion of the sale, the chief operating officer owned 63,344 shares of the company’s stock, valued at $990,700.16. The trade was a 64.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. 2.98% of the stock is currently owned by company insiders.

About Dynavax Technologies

Dynavax Technologies Corporation is a biopharmaceutical company focused on the development and commercialization of novel vaccines and immunotherapies. Headquartered in Emeryville, California, the company specializes in leveraging its proprietary Toll-like receptor (TLR) agonist platform to enhance immune responses. Its lead product, HEPLISAV-B, is a two-dose hepatitis B vaccine approved by the U.S. Food and Drug Administration that incorporates the CpG 1018 adjuvant to stimulate a rapid and robust antibody response in adults.

Founded in 1993, Dynavax has built a pipeline that extends beyond hepatitis B to include candidates targeting seasonal influenza, respiratory syncytial virus (RSV) and emerging infectious diseases.